The heavily mutated Omicron coronavirus variant is likely to spread internationally and poses a very high risk of infection surges that could have “severe consequences” in some places, the World Health Organization (WHO) said on November 29.
If you are not happy with the results below please do another search
50 search results for:
Thermo Fisher Scientific Inc. said on November 29 the company’s COVID-19 diagnostic tests can accurately detect the new coronavirus variant Omicron that has made several countries shut their borders.
The top U.S. infectious disease official, Dr. Anthony Fauci, told President Joe Biden on November 28 it will take about two weeks to have definitive information on the new coronavirus variant Omicron that has sparked new travel restrictions and shaken financial markets.
The Omicron coronavirus variant spread around the world on November 28, with new cases found in the Netherlands, Denmark and Australia even as more countries imposed travel restriction to try to seal themselves off.
Member states of the World Health Organization reached a tentative consensus to negotiate a future agreement on preventing pandemics, bridging the gap between sides led by the European Union and United States, diplomats said on November 28.
The World Health Organization (WHO) said on November 28 that it is not yet clear if the new Omicron coronavirus variant is more transmissible compared to other SARS-CoV-2 variants or if it causes more severe disease.
U.S. President Joe Biden said on November 26 his administration was not considering new vaccine mandates following the discovery of a new COVID-19 variant in South Africa, which led to travel bans from that country and seven other nations.
Novavax Inc. said on November 26 the company had started working on a version of a COVID-19 vaccine to target the variant detected in South Africa and would have the shot ready for testing and manufacturing in the next few weeks.
Moderna Inc. announced updates to the biotechnology company’s strategy to address SARS-CoV-2 variants of concern, given the emergence of the B.1.1.529 (Omicron) variant.
Merck & Co. said on November 26 updated data from the company’s study of the experimental COVID-19 pill molnupiravir showed the drug was significantly less effective in cutting hospitalizations and deaths than previously reported.